Summit Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 16.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 12.82B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto...